Regramostim

Highest phase reached

Phase 3

www.ebi.ac.uk

Drug type

Protein

www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Phase 3
www.ebi.ac.uk

Drug type: Protein
www.ebi.ac.uk

Drug name: Regramostim
www.ebi.ac.uk

colony stimulating factor 2 human clone pcsf 1 protein moiety reduced glycoform gmc 89 107
COLONY-STIMULATING FACTOR 2 (HUMAN CLONE PCSF-1 PROTEIN MOIETY REDUCED), GLYCOFORM GMC 89-107
gm csf
gm csf cho cell
GM-CSF
GM-CSF (CHO CELL)
gmc 89 107
GMC 89-107
GMC-89-107
high dose recombinant sars cov 2 vaccine cho cell
high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Human Erythropoiesis Injection (CHO cell)
inhaled molgramostim (rhGM-CSF)
leucotropin glycoform gmc 89 107
Leucotropin glycoform gmc 89-107
low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Part1:Recombinant two-component COVID-19 vaccine (CHO cell)
Part2: Recombinant two-component COVID-19 vaccine (CHO cell)
Recombinant COVID-19 vaccine (CHO cell)
Recombinant COVID-19 Vaccine (CHO cell)
Recombinant COVID-19 Vaccine (CHO Cell)
Recombinant COVID-19 vaccine(CHO cell)
Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)
Recombinant Human Erythropoiesis Injection (CHO cell)
recombinant human Thrombin(CHO cell)

And 32 more, listed on the interactive page.

CAS registry numbers

127757-91-9

ChEMBL ID: CHEMBL2107881
www.ebi.ac.uk

FDA ingredient codes (UNII)

KR89Q40F01

Patents: 0
Designations: 1
First in class: No
Fast track: No
Breakthrough designation: No
Orphan designation: No
Priority review: No
Orphan exclusivity: No
Accelerated approval: No

Drug name stem: -stim; -stim

Mechanisms of action

Mechanism
Granulocyte colony stimulating factor receptor agonist
Action type
Agonist
Target
Granulocyte colony-stimulating factor receptor
Protein identifier
Q99062

Open Targets mechanisms

Mechanism
Granulocyte colony stimulating factor receptor agonist
Action type
Agonist
Target
Granulocyte colony-stimulating factor receptor

Condition
HIV Infections
Highest recorded phase
2
Condition identifier
EFO:0000180
Subject identifier
D015658
Condition
Burkitt Lymphoma
Highest recorded phase
2
Condition identifier
EFO:0000309
Subject identifier
D002051
Condition
Colorectal Neoplasms
Highest recorded phase
2
Condition identifier
EFO:0000365
Subject identifier
D015179
Condition
Melanoma
Highest recorded phase
3
Condition identifier
EFO:0000389
Subject identifier
D008545
Condition
Lymphoma, Large B-Cell, Diffuse
Highest recorded phase
2
Condition identifier
EFO:0000403
Subject identifier
D016403
Condition
Glioblastoma
Highest recorded phase
2
Condition identifier
EFO:0000519
Subject identifier
D005909
Condition
Lymphoma
Highest recorded phase
2
Condition identifier
EFO:0000574
Subject identifier
D008223
Condition
Neuroblastoma
Highest recorded phase
2
Condition identifier
EFO:0000621
Subject identifier
D009447
Condition
Carcinoma, Renal Cell
Highest recorded phase
2
Condition identifier
EFO:0000681
Subject identifier
D002292
Condition
Melanoma
Highest recorded phase
3
Condition identifier
EFO:0000756
Subject identifier
D008545
Condition
HIV Infections
Highest recorded phase
2
Condition identifier
EFO:0000764
Subject identifier
D015658
Condition
Mesothelioma
Highest recorded phase
2
Condition identifier
EFO:0000770
Subject identifier
D008654
Condition
Multiple Myeloma
Highest recorded phase
1
Condition identifier
EFO:0001378
Subject identifier
D009101
Condition
Carcinoma, Non-Small-Cell Lung
Highest recorded phase
2
Condition identifier
EFO:0003060
Subject identifier
D002289
Condition
Nasopharyngeal Neoplasms
Highest recorded phase
2
Condition identifier
EFO:0004252
Subject identifier
D009303
Condition
Peripheral Arterial Disease
Highest recorded phase
2
Condition identifier
EFO:0004265
Subject identifier
D058729
Condition
Appendicitis
Highest recorded phase
2
Condition identifier
EFO:0007149
Subject identifier
D001064
Condition
Varicose Ulcer
Highest recorded phase
2
Condition identifier
EFO:1001923
Subject identifier
D014647
Condition
Colorectal Neoplasms
Highest recorded phase
2
Condition identifier
EFO:1001951
Subject identifier
D015179
Condition
Pulmonary Alveolar Proteinosis
Highest recorded phase
2
Condition identifier
MONDO:0001437
Subject identifier
D011649
Condition
Kidney Neoplasms
Highest recorded phase
1
Condition identifier
MONDO:0002367
Subject identifier
D007680
Condition
Neoplasms
Highest recorded phase
1
Condition identifier
MONDO:0004992
Subject identifier
D009369
Condition
Breast Neoplasms
Highest recorded phase
2
Condition identifier
MONDO:0007254
Subject identifier
D001943
Condition
Ovarian Neoplasms
Highest recorded phase
2
Condition identifier
MONDO:0008170
Subject identifier
D010051
Condition
Prostatic Neoplasms, Castration-Resistant
Highest recorded phase
2
Condition identifier
MONDO:0008315
Subject identifier
D064129

And 3 more, listed on the interactive page.

Condition identifier
EFO_0000180
Condition identifier
EFO_0000365
Highest recorded phase
1
Condition identifier
EFO_0000389
Condition identifier
EFO_0000519
Highest recorded phase
2
Condition identifier
EFO_0000574
Highest recorded phase
2
Condition identifier
EFO_0000618
Condition identifier
EFO_0000621
Highest recorded phase
2
Condition identifier
EFO_0000681
Highest recorded phase
3
Condition identifier
EFO_0000756
Highest recorded phase
3
Condition identifier
EFO_0000764
Highest recorded phase
2
Condition identifier
EFO_0001378
Highest recorded phase
2
Condition identifier
EFO_0003060
Highest recorded phase
2
Condition identifier
EFO_0004252
Highest recorded phase
2
Condition identifier
EFO_0004265
Highest recorded phase
2
Condition identifier
EFO_0007149
Highest recorded phase
2
Condition identifier
EFO_1000211
Highest recorded phase
2
Condition identifier
EFO_1001829
Highest recorded phase
2
Condition identifier
EFO_1001904
Highest recorded phase
2
Condition identifier
EFO_1001923
Highest recorded phase
2
Condition identifier
EFO_1001927
Highest recorded phase
1
Condition identifier
HP_0000789
Condition identifier
HP_0001394
Condition identifier
HP_0100806
Highest recorded phase
2
Condition identifier
MONDO_0001056
Highest recorded phase
2
Condition identifier
MONDO_0001437
Highest recorded phase
2

And 80 more, listed on the interactive page.

Event
alanine aminotransferase abnormal
Reports
6
Reporting signal score
18.093
Event
aspartate aminotransferase abnormal
Reports
7
Reporting signal score
25.0595
Event
bone marrow failure
Reports
12
Reporting signal score
14.382
Event
bone pain
Reports
21
Reporting signal score
26.8779
Event
capillary leak syndrome
Reports
6
Reporting signal score
17.466
Event
chest pain
Reports
26
Reporting signal score
12.8805
Event
chills
Reports
32
Reporting signal score
32.9116
Event
device related bacteraemia
Reports
17
Reporting signal score
113.139
Event
dyspnoea
Reports
60
Reporting signal score
21.5738
Event
febrile neutropenia
Reports
4
Reporting signal score
6.21572
Event
frostbite
Reports
1
Reporting signal score
5.90286
Event
hyperhidrosis
Reports
34
Reporting signal score
36.1004
Event
hypotension
Reports
52
Reporting signal score
40.881
Event
hypoxia
Reports
14
Reporting signal score
16.3108
Event
karyotype analysis abnormal
Reports
1
Reporting signal score
6.41328
Event
low birth weight baby
Reports
3
Reporting signal score
9.56339
Event
mutagenic effect
Reports
1
Reporting signal score
7.91689
Event
obstruction gastric
Reports
5
Reporting signal score
17.216
Event
premature baby
Reports
3
Reporting signal score
5.75674
Event
pupillary reflex impaired
Reports
2
Reporting signal score
8.52392
Event
pyrexia
Reports
66
Reporting signal score
42.5867
Event
refractory cancer
Reports
1
Reporting signal score
5.7319
Event
small intestinal obstruction
Reports
9
Reporting signal score
14.8089
Event
syncope
Reports
32
Reporting signal score
30.7008
Event
transfusion reaction
Reports
4
Reporting signal score
13.9125

And 1 more, listed on the interactive page.

NCT00001237
clinicaltrials.gov
NCT00208975
clinicaltrials.gov
NCT00272493
clinicaltrials.gov
NCT00429416
clinicaltrials.gov
NCT00458536
clinicaltrials.gov
NCT00458601
clinicaltrials.gov
NCT00524277
clinicaltrials.gov
NCT00841399
clinicaltrials.gov
NCT00854789
clinicaltrials.gov
NCT00582140
clinicaltrials.gov
NCT00849121
clinicaltrials.gov
NCT01341652
clinicaltrials.gov
NCT01784913
clinicaltrials.gov
NCT02452307
clinicaltrials.gov
NCT00969722
clinicaltrials.gov
NCT01757626
clinicaltrials.gov
NCT06013618
clinicaltrials.gov
NCT01041417
clinicaltrials.gov
NCT01176552
clinicaltrials.gov
NCT01232712
clinicaltrials.gov
NCT01265433
clinicaltrials.gov
NCT01890980
clinicaltrials.gov
NCT01329809
clinicaltrials.gov
NCT01363206
clinicaltrials.gov
NCT01368276
clinicaltrials.gov

And 16 more, listed on the interactive page.

Prodrug: No
Chirality: Single enantiomer
Inorganic: No
Natural product: No

Related records

Trials (291)

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow
A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster
A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)
A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination
A Clinical Trial on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical Routes
A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)
A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19
A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF
A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
A Phase 2 Clinical Study of Pegerythropoietin Injection (RD01) for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis
A Phase 2 Trial for Patients With Metastatic Solid Cancer
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.

In development for (28)

Adult acute respiratory distress syndrome Phase 2
Appendicitis Phase 2
Autoimmune pulmonary alveolar proteinosis Phase 2
Breast cancer Phase 2
Burkitt lymphoma Phase 2
Cancer Phase 1
Colorectal adenocarcinoma Phase 2
Colorectal carcinoma Phase 2
Cutaneous melanoma Phase 3
Diffuse large B-cell lymphoma Phase 2
Glioblastoma Phase 2
HIV infectious disease Phase 2
Kidney cancer Phase 1
Lung cancer Phase 2
Lymphoma Phase 2
Malignant colon neoplasm Phase 2
Malignant glioma Phase 2
Malignant pleural mesothelioma Phase 2
Melanoma Phase 3
Nasopharyngeal neoplasm Phase 2

Targets (1)

CSF3R Granulocyte colony stimulating factor receptor agonist

Regramostim

Development status

Names and chemistry

Other names (57)

Identifiers

Regulatory information

Other regulatory facts

Pharmacology

Drug classification

Mechanisms of action

Open Targets mechanisms

Investigated indications (28)

Open Targets indications (105)

Reported adverse events (26)

Trial references (41)

Chemical properties

Related records

Trials (291)

In development for (28)

Other linked conditions (1)

Targets (1)